(CIDRAP News) The federal government announced plans today to buy 20,000 treatment courses of an experimental anthrax antitoxin from Human Genome Sciences Inc. (HGS) for $165 million.
Full payment for the product, called ABthrax, is contingent on its licensing by the Food and Drug Administration (FDA), the Department of Health and Human Services (HHS) said in a news release.